Dr. Raina is a board-certified cardiologist in the General Cardiology clinic at Stanford Health Care and a member of the Stanford Cardiovascular Institute. He is also a clinical associate professor in the Division of Cardiovascular Medicine.
His clinical interests include preventive cardiology, cardiac rehabilitation, and sports cardiology. In his recent positions at West Virginia University, he established the cardiology telemedicine program during and after the COVID pandemic. He applied his passion for cardiac rehab by creating individualized treatment plans for college athletes recovering from COVID. Dr. Raina is also passionate about building relationships with community doctors. He believes continuous communication is an essential part of excellent patient care.
Dr. Raina’s current research focuses on preventive cardiology, cardiac imaging, and outcomes research. He studies the outcomes of different cardiac interventions in specific patient populations. His research helps identify appropriate treatments for patients who have other conditions in addition to heart disease.
Dr. Raina eagerly anticipates joining the faculty of the Stanford South Asian Translational Heart Initiative (SSATHI). He is excited for the opportunity to address the high risk of cardiovascular diseases among South Asians. He looks forward to applying his clinical and research experience to support SSATHI’s mission to provide advanced care to ethnic populations disproportionately affected by these diseases.
Dr. Raina is a peer reviewer for several prestigious publications, including Neuropsychiatric Disease and Treatment and the International Journal of Chronic Obstructive Pulmonary Disease. He has also been an invited guest speaker at national and international meetings, including those for the International Congress of Cardiology and the World Congress of Cardiothoracic-Renal Diseases.
Dr. Raina is a fellow of the American College of Cardiology (FACC) and a member of the American College of Cardiology.
- Cardiovascular Disease
Honors & Awards
Darden Merit Scholarship for Outstanding Academic Performance, University of Virginia Darden School of Business
Board Certification: National Board of Echocardiography, Adult Echocardiography (2016)
Board Certification: American Board of Internal Medicine, Internal Medicine (2013)
Board Certification: American Board of Internal Medicine, Cardiovascular Disease (2016)
Fellowship: University of Arkansas for Medical Sciences Medical Center (2016) AR
Residency: University of Arkansas Internal Medicine (2013) AR
Medical Education: Armed Forces Medical College (2004) India
Additional Clinical Info
Trends and Outcomes of Type 2 Myocardial Infarction During the COVID-19 Pandemic in the United States.
Korean circulation journal
BACKGROUND AND OBJECTIVES: There is limited data on the impact of type 2 myocardial infarction (T2MI) during the coronavirus disease 2019 (COVID-19) pandemic.METHODS: The National Inpatient Sample (NIS) database from January 2019 to December 2020 was queried to identify T2MI hospitalizations based on the appropriate International Classification of Disease, Tenth Revision-Clinical Modification codes. Monthly trends of COVID-19 and T2MI hospitalizations were evaluated using Joinpoint regression analysis. In addition, the multivariate logistic and linear regression analysis was used to compare in-hospital mortality, coronary angiography use, and resource utilization between 2019 and 2020.RESULTS: A total of 743,535 patients hospitalized with a diagnosis of T2MI were identified in the years 2019 (n=331,180) and 2020 (n=412,355). There was an increasing trend in T2MI hospitalizations throughout the study period corresponding to the increase in COVID-19 hospitalizations in 2020. The adjusted odds of in-hospital mortality associated with T2MI hospitalizations were significantly higher in 2020 compared with 2019 (11.1% vs. 8.1%: adjusted odds ratio, 1.19 [1.13-1.26]; p<0.01). In addition, T2MI hospitalizations were associated with lower odds of coronary angiography and higher total hospitalization charges, with no difference in the length of stay in 2020 compared with 2019.CONCLUSIONS: We found a significant increase in T2MI hospitalizations with higher in-hospital mortality, total hospitalization costs, and lower coronary angiography use during the early COVID-19 pandemic corresponding to the trends in the rise of COVID-19 hospitalizations. Further research into the factors associated with increased mortality can increase our preparedness for future pandemics.
View details for DOI 10.4070/kcj.2023.0063
View details for PubMedID 37880873
Intracranial bleeding and associated outcomes in atrial fibrillation patients undergoing percutaneous left atrial appendage occlusion: Insights from National Inpatient Sample 2016-2020.
Heart rhythm O2
2023; 4 (7): 433-439
Background: Percutaneous left atrial appendage occlusion (LAAO) has proved to be a safer alternative for long-term anticoagulation; however, patients with a history of intracranial bleeding were excluded from large randomized clinical trials.Objective: The purpose of this study was to determine outcomes in atrial fibrillation (AF) patients with a history of intracranial bleeding undergoing percutaneous LAAO.Methods: National Inpatient Sample and International Classification of Diseases, Tenth Revision, codes were used to identify patients with AF who underwent LAAO during the years 2016-2020. Patients were stratified based on a history of intracranial bleeding vs not. The outcomes assessed in our study included complications, in-hospital mortality, and resource utilization.Result: A total of 89,300 LAAO device implantations were studied. Approximately 565 implantations (0.6%) occurred in patients with a history of intracranial bleed. History of intracranial bleeding was associated with a higher prevalence of overall complications and in-patient mortality in crude analysis. In the multivariate model adjusted for potential confounders, intracranial bleeding was found to be independently associated with in-patient mortality (adjusted odds ratio [aOR] 4.27; 95% confidence interval [CI] 1.68-10.82); overall complications (aOR 1.74; 95% CI 1.36-2.24); prolonged length of stay (aOR 2.38; 95% CI 1.95-2.92); and increased cost of hospitalization (aOR 1.28; 95% CI 1.08-1.52) after percutaneous LAAO device implantation.Conclusion: A history of intracranial bleeding was associated with adverse outcomes after percutaneous LAAO. These data, if proven in a large randomized study, can have important clinical consequences in terms of patient selection for LAAO devices.
View details for DOI 10.1016/j.hroo.2023.06.002
View details for PubMedID 37520018